Jyoti Jha


  • MSc (Area): Biotechnology
  • jyoti_16541@yenepoya.edu.in


I Jyoti Jha born and brought up in Mumbai, but my native is Bihar. I completed my Bachelor’s in Biotechnology from Mumbai in 2016. Later, obtained Master’s degree in Biotechnology from Mount Carmel College, Bengaluru in 2018. I worked as a Clinical Research Associate (CRA) in the Forte Research Systems Pvt Ltd, Bengaluru from June 2018 to February 2020, where I was trained in Designing Schedule of Events (SOE) from the Clinical trial protocols. I had to resign from the post CRA, as I realized that my interest lies in Research in Life Sciences. I am a person that believes in perseverance and follows it. I am a keen learner and gets overwhelmed when the learned knowledge is shared that is why research is the right place for these traits. At CSBMM, I am working towards establishing Mass spectrometry based molecular assays for lung tumors.


  • Clinical Research Associate (CRA) – Forte Research Systems Pvt Ltd, Bengaluru 

Awards/ Honors

  • Qualified the National Eligibility Test (NET) conducted by the Council of Scientific and Industrial Research, Government of India in LS category with an All-India Rank of 53
  • Qualified Maharashtra State Eligibility Test (MHSET) for Assistant Professor Accredited by U.G.C. & Conducted by Savitribai Phule Pune University held on 27th December 2020 in the subject Life Sciences (Valid in the States of Maharashtra & Goa only)




Research Interest/Area

Cancer Biology, Signaling pathways, Biochemistry, Genetics and Bioinformatics


Lung cancer is the second most commonly diagnosed cancer in 2020 and ranking first in the death rate of men. The prevalence of lung cancer is more because of late detection and poor treatment. Mostly it is detected at Stage IIIa or IV, by that time surgical removal of tumor or radiation therapy won’t be an option. The existing detection assays/markers still belongs to “research” category, and the NCCN (National Comprehensive Cancer Network) has not yet recommended universal testing method for lung cancer markers. IHC (Immunohistochemistry) although being the most abundantly used technique in biomarker detection for lung cancer it lacks in fitting into the exact definition of ideal biomarker detection technique by being time-consuming, requiring multiple sections of tumor tissue (small tumor specimen, one of the major challenge in lung cancer biomarker detection), showing cross-reaction with other tissue types and tumors and producing different staining patterns of different clones of the same antibody. Considering the limitations of IHC, the current interest for detection/early diagnosis/diagnosis is towards the technique that can overcome the limitations of IHC and provide high throughput results with high specificity and sensitivity. One such technique involves the use of Mass Spectrometry. The extensive and evolutionary research on identifying the exact biomarkers or panel of it for specific lung cancer tumor have provided a lot of information pertaining to different proteins as biomarkers, now with this extensive information a specific and sensitive assay establishment using mass spectrometry for the diagnosis of molecular markers of lung cancer will give surety to the pathologist in determining the type of tumor and to clinicians in determining the treatment which is specific to the type of tumor identified.